Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMolina Healthcare Adzynma Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C27325-A

    Adzynma Coverage for Congenital Thrombotic Thrombocytopenic Purpura

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C27325-A alerts

    Get alerted when Policy C27325-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for intravenous Adzynma as prophylactic or on-demand enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura in adult and pediatric members. Coverage requires documented diagnosis, laboratory and genetic confirmation, treatment planning, specialist involvement, and response at renewal.

    Policy Summary
    PayerMolina Healthcare
    PolicyAdzynma Coverage for Congenital Thrombotic Thrombocytopenic Purpura
    Policy CodePolicy C27325-A
    Change TypeNo material clinical or coverage changes
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionDocument congenital TTP by molecular genetic testing and ADAMTS13 activity below 10% of normal measured by the FRETS-VWF73 assay.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial authorization
    12 monthsContinuation authorization
    40 IU/kg every other weekStandard prophylactic dose
    NoneAge restriction

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    IntravenousAdministration route

    Coverage Criteria

    Initial Therapy Criteria

    Covered for congenital thrombotic thrombocytopenic purpura when ALL of the following are met:

    All required criteria

    • Diagnosis: The member has a documented diagnosis of congenital thrombotic thrombocytopenic purpura.
    • Diagnostic confirmation: The diagnosis is confirmed by molecular genetic testing, and ADAMTS13 activity is less than 10% of normal as measured by the fluorescent resonance energy transfer-von Willebrand factor 73 (FRETS-VWF73) assay.ADAMTS13 activity <10% of normal

      Documentation required.

    • Treatment plan: The member's prophylactic treatment plan, if applicable, and on-demand treatment plan are documented.

      Documentation required.

    • Baseline assessment: The prescriber's baseline disease activity evaluation and treatment goals are documented for use in evaluating efficacy at renewal.
    • Contraindication review: The prescriber attests, or the clinical reviewer determines, that the member does not have an FDA-labeled contraindication that has not been addressed in the submitted documentation.

      Contraindications include life-threatening hypersensitivity reactions to Adzynma or its components.

    Continuation Therapy Criteria

    Covered for continuation when ALL of the following are met:

    All required criteria

    • Safety: There is no evidence of intolerable adverse effects or drug toxicity.
    • Clinical response: Documentation demonstrates a positive clinical response, as evidenced by low disease activity and/or improvement in the condition's signs and symptoms.

      Documentation required.

    No compendial approved off-label uses are listed for Adzynma.

    Uses of Adzynma outside the policy-covered indication are considered experimental or investigational and follow Molina’s Off-Label policy.

    Adzynma is contraindicated for patients who have manifested life-threatening hypersensitivity reactions to Adzynma or any of its components.

    Coding and Billing

    Coding/Billing InformationHCPCS
    J7171Injection, adamts13, recombinant-krhn, 10 iu
    ADAMTS13 Activity
    Required activity levelLess than 10% of normal ADAMTS13 activity
    AssayFluorescent resonance energy transfer-von Willebrand factor 73 (FRETS-VWF73) assay
    UseUsed to confirm the diagnosis of congenital thrombotic thrombocytopenic purpura with molecular genetic testing

    Prior Authorization and Documentation

    Prior Authorization

    Initial Prior Authorization Criteria

    Submit an initial prior authorization request demonstrating that the member has congenital thrombotic thrombocytopenic purpura (TTP) and meets Molina’s clinical criteria for Adzynma.

    • Diagnosis is confirmed by molecular genetic testing.
    • ADAMTS13 activity is <10% of normal, measured by the FRETS-VWF73 assay.
    • A prophylactic, if applicable, and on-demand treatment plan is documented.
    • The prescriber documents baseline disease activity and treatment goals for evaluating efficacy at renewal.
    • The prescriber attests, or the clinical reviewer determines, that no unaddressed FDA-labeled contraindication is present.
    Prior Authorization

    Continuation Prior Authorization

    Continuation authorization is issued for 12 months when the prescriber documents that therapy remains tolerable and effective. Initial authorization is also issued for 12 months.

    Clinical Background

    Thrombotic thrombocytopenic purpura is a thrombotic microangiopathy caused by severely reduced activity of the von Willebrand factor-cleaving protease ADAMTS13. Congenital TTP results from biallelic pathogenic variants in the ADAMTS13 gene and may cause platelet-rich thrombi, organ ischemia, neurologic abnormalities, kidney dysfunction, thrombocytopenia, and microangiopathic hemolytic anemia. Adzynma is recombinant ADAMTS13 enzyme replacement administered intravenously for prophylactic or on-demand treatment.

    Definitions

    Congenital Thrombotic Thrombocytopenic Purpura
    ConditionCongenital thrombotic thrombocytopenic purpura (cTTP)
    Underlying deficiencySevere deficiency of the ADAMTS13 protease
    Genetic causeBiallelic germline pathogenic variants in the ADAMTS13 gene
    ADAMTS13
    名称ADAMTS13 is the von Willebrand factor-cleaving protease
    Clinical roleSevere deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura
    Adzynma functionAdzynma provides replacement for low levels of the deficient enzyme in patients with cTTP

    Initial Therapy

    Initial Therapy Criteria

    Initial therapy is covered when ALL of the following are met:

    All required criteria

    • Diagnosis: The member has a documented diagnosis of congenital thrombotic thrombocytopenic purpura.
    • Diagnostic confirmation: The diagnosis is confirmed by molecular genetic testing, and ADAMTS13 activity is less than 10% of normal as measured by the fluorescent resonance energy transfer-von Willebrand factor 73 (FRETS-VWF73) assay.ADAMTS13 activity <10% of normal

      Documentation required.

    • Treatment plan: The member's prophylactic treatment plan, if applicable, and on-demand treatment plan are documented.

    Continuation Therapy

    Continuation Criteria

    Continuation therapy is covered for 12 months when ALL of the following are met:

    All required criteria

    • Safety: There is no evidence of intolerable adverse effects or drug toxicity.
    • Clinical response: Documentation demonstrates a positive clinical response, as evidenced by low disease activity and/or improvement in the condition's signs and symptoms.

      Documentation required.

    Dosing and Quantity Limits

    Adzynma Prophylactic Dosing
    Standard prophylactic dose40 IU/kg body weight once every other week
    Response-based optionA higher dose of 40 IU/kg body weight once weekly may be provided based on clinical response with medical record documentation support
    Dispensing limitOne month per dispense
    Adzynma On-Demand Dosing
    Day 140 IU/kg body weight
    Day 220 IU/kg body weight
    Day 3 and beyond15 IU/kg body weight until two days after the acute event is resolved

    Site of Care

    Billing Rule

    Use the appropriate hospital outpatient benefit

    For infused medication administered in a non-inpatient hospital facility-based location, pharmacy or medical benefit coverage is recommended.

    Policy Summary
    PayerMolina Healthcare
    PolicyAdzynma Coverage for Congenital Thrombotic Thrombocytopenic Purpura
    Policy CodePolicy C27325-A
    Change TypeNo material clinical or coverage changes
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionDocument congenital TTP by molecular genetic testing and ADAMTS13 activity below 10% of normal measured by the FRETS-VWF73 assay.
    SourceLink
    On This Page
    Coverage CriteriaCoding and BillingPrior Authorization and DocumentationClinical BackgroundDefinitionsInitial TherapyContinuation TherapyDosing and Quantity LimitsSite of Care
  1. No evidence of intolerable adverse effects or drug toxicity.
  2. Positive clinical response demonstrated by low disease activity and/or improvement in signs and symptoms.
  3. Continuation authorization period: 12 months.
  4. Documentation Required

    Medical Records and Supporting Documentation

    Include sufficient medical records and supporting documentation for Molina’s coverage determination. Molina may request patient records, test results, and credentials of the provider ordering or performing the drug or service.

    • Additional information may be required on a case-by-case basis, including when an updated FDA label has been issued within the prior 180 days.
    • Inadequate documentation may result in denial of reimbursement or other appropriate action when medical necessity, non-investigational use, benefit eligibility, or appropriate billing is not established.
    Documentation Required

    Genetic and ADAMTS13 Testing

    Submit the molecular genetic test results confirming the diagnosis and the ADAMTS13 activity result used to establish eligibility.

    • ADAMTS13 activity must be <10% of normal.
    • Testing must be performed using the fluorescent resonance energy transfer-von Willebrand factor 73 (FRETS-VWF73) assay.
    • Molecular genetic confirmation and the ADAMTS13 result are required documentation.
    Documentation Required

    Treatment Plan Documentation

    Document the member-specific treatment plan supporting the requested use of Adzynma.

    • Provide the prophylactic treatment plan, if applicable.
    • Provide the on-demand treatment plan.
    Documentation Required

    Baseline Disease Activity and Treatment Goals

    Before initial authorization, submit the prescriber’s assessment of baseline disease activity and the goals of treatment that will be used to evaluate efficacy at renewal.

    • Describe the member’s baseline disease activity.
    • State measurable or clinically assessable treatment goals for renewal review.
    Documentation Required

    Renewal Response Documentation

    For renewal, submit documentation showing a positive clinical response to Adzynma.

    • Document low disease activity and/or improvement in the condition’s signs and symptoms.
    Documentation Required

    Specialist Consultation Notes

    Adzynma must be prescribed by or in consultation with an appropriate board-certified specialist.

    • Acceptable prescribers or consultants include a hematologist, oncologist, intensive care specialist, or specialist in rare genetic hematologic diseases.
    • When prescribed in consultation, submit the consultation notes with the initial request and with each reauthorization request.
    Documentation Required

    Member-Specific Dosing Measurement

    When Adzynma dosing is based on a member-specific measurement, include that measurement with the medical necessity request.

    • Submit the member’s weight, body surface area, or other applicable member-specific dosing measurement, as required by the prescribed dosing method.
    Denial Risk

    Documentation Failure May Result in Denial

    Molina may deny coverage or reimbursement when the submitted documentation does not support medical necessity or establish that the requested use is not investigational or experimental.

    • Documentation must support that the drug is medically necessary and within the member’s benefit scope.
    • Molina may also take appropriate action when records demonstrate inappropriate or excessive billing or other practice concerns.
    Denial Risk

    FDA-Labeled Contraindications

    Coverage requires that the prescriber address FDA-labeled contraindications in the submitted documentation and that no unaddressed contraindication is present.

    • The prescriber must attest, or the clinical reviewer must determine, that no unaddressed FDA-labeled contraindication applies.
    Denial Risk

    Continuation Denial Conditions

    Continuation coverage may be denied when Adzynma is not tolerated or does not demonstrate the required clinical response.

    • Intolerable adverse effects or drug toxicity are not acceptable for continued coverage.
    • Renewal requires positive clinical response shown by low disease activity and/or improvement in signs and symptoms.
    Denial Risk

    Experimental or Investigational Use

    Uses of Adzynma outside the covered indication are considered experimental or investigational and are subject to Molina’s Off-Label policy.

    • All other uses are excluded from coverage under the covered indication criteria.
    Denial Risk

    Life-Threatening Hypersensitivity

    Life-threatening hypersensitivity to Adzynma or any of its components is a contraindication to coverage.

    • Do not request coverage when the member has manifested a life-threatening hypersensitivity reaction to Adzynma or its components.
    Thrombotic Thrombocytopenic Purpura
    ConditionThrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy
    ThrombiArteriolar platelet-rich thrombi
    Organ effectsThe thrombi cause organ ischemia and produce neurologic abnormalities, kidney dysfunction, thrombocytopenia, and microangiopathic hemolytic anemia
    TTP Associated With Severe ADAMTS13 Reduction
    CauseTTP is caused by severely reduced activity of the ADAMTS13 protease
    Vascular findingThe condition is characterized by arteriolar platelet-rich thrombi
    Associated effectsIt may cause organ ischemia, neurologic abnormalities, kidney dysfunction, thrombocytopenia, and microangiopathic hemolytic anemia
    Congenital TTP Terminology
    DefinitionCongenital TTP is severe ADAMTS13 deficiency due to biallelic germline pathogenic variants in the ADAMTS13 gene
    InheritancecTTP is autosomal recessive; pathogenic variants affecting both alleles are required to cause deficiency severe enough to lead to the clinical syndrome
    Alternate terminologyAlso called hereditary TTP (hTTP), inherited TTP, familial TTP, or Upshaw-Schulman syndrome
    Genetic Confirmation of Hereditary TTP
    Definitive confirmationIdentification of biallelic pathogenic variants in ADAMTS13 confirms hereditary TTP
    Appropriate testing contextGenetic testing is appropriate in an individual with suspected hereditary TTP based on undetectable or severely deficient ADAMTS13 activity without an inhibitor
    Variant statusIndividuals heterozygous for a pathogenic ADAMTS13 variant are considered unaffected

    Documentation required.

  5. Baseline assessment: The prescriber's baseline disease activity evaluation and treatment goals are documented for use in evaluating efficacy at renewal.
  6. Contraindication review: The prescriber attests, or the clinical reviewer determines, that the member does not have an FDA-labeled contraindication that has not been addressed in the submitted documentation.

    Contraindications include life-threatening hypersensitivity reactions to Adzynma or its components.

  7. Dispensing limitThree on-demand doses per dispense